tiprankstipranks

Boston Scientific price target raised to $117 from $101 at Canaccord

Canaccord raised the firm’s price target on Boston Scientific (BSX) to $117 from $101 and keeps a Buy rating on the shares. The firm said they reported solid Q4 results capping off a spectacular year of growth for the Med-Tech strategic. Given the scarcity of strategics with this sort of momentum, Canaccord thinks they likely could weather the optics of deceleration – especially if the company continues to augment growth with the heightened level of M&A occurring in the Med-Tech space.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue